トピックス New Scientific Outputs related to COVID-19
トピックス
5. Report on Rapid and accurate detection of novel coronavirus SARS-CoV-2 using CRISPR-Cas3 |
---|
Title: Rapid and accurate detection of novel coronavirus SARS-CoV-2 using CRISPR-Cas3 Preprint server: MedRxivPosted Date: 2020/6/2 URL: https://www.medrxiv.org/content/10.1101/2020.06.02.20119875v1 Authors: Kazuto Yoshimi, Kohei Takeshita, Seiya Yamayoshi, Satomi Shibumura, Yuko Yamauchi, Masaki Yamamoto, Hiroshi Yotsuyanagi, Yoshihiro Kawaoka, Tomoji Mashimo |
Outline: (Last updated: 2020/06/05)
|
4. Report on SARS-CoV-2 ORF3b is a potent interferon antagonist whose activity is further increased by a naturally occurring elongation variant |
---|
Title: SARS-CoV-2 ORF3b is a potent interferon antagonist whose activity is further increased by a naturally occurring elongation variant Preprint server: BioRxivPosted Date: 2020/5/11 URL: https://doi.org/10.1101/2020.05.11.088179 Authors: Yoriyuki Konno, Izumi Kimura, Keiya Uriu, Masaya Fukushi, Takashi Irie, Yoshio Koyanagi, So Nakagawa, Kei Sato |
Outline: 概要: (Last updated: 2020/06/05)
|
3. Report on docking model and pharmacological activity of Nelfinavir |
---|
Title: Multidrug treatment with nelfinavir and cepharanthine against COVID-19 Preprint server: BioRxivPosted Date: 2020/4/14 DOI: https://doi.org/10.1101/2020.04.14.039925 Authors: Hirofumi Ohashi, Koichi Watashi, Wakana Saso, Kaho Shionoya, Shoya Iwanami, Takatsugu Hirokawa, Tsuyoshi Shirai, Shigehiko Kanaya, Yusuke Ito, Kwang Su Kim, Kazane Nishioka, Shuji Ando, Keisuke Ejima, Yoshiki Koizumi, Tomohiro Tanaka, Shin Aoki, Kouji Kuramochi, Tadaki Suzuki, Katsumi Maenaka, Tetsuro Matano, Masamichi Muramatsu, Masayuki Saijo, Kazuyuki Aihara, Shingo Iwami, Makoto Takeda, Jane A. McKeating, Takaji Wakita |
Outline: Mathematical modeling in vitro antiviral activity coupled with the known pharmacokinetics for these drugs predicts that Nelfinavir will facilitate viral clearance. Combining Nelfinavir/Cepharanthine enhanced their predicted efficacy to control viral proliferation, to ameliorate both the progression of disease and risk of transmission. In summary, this study identifies a new multidrug combination treatment for COVID-19. 概要:
(Last updated: 2020/06/05)
|
2. Report on Knowledge-based structural models of SARS-CoV-2 proteins and their complex with potential drugs |
---|
Title: Knowledge-based structural models of SARS-CoV-2 proteins and their complex with potential drugs Preprint server: ChemRxivPosted Date: 2020/03/24 URL: https://chemrxiv.org/articles/Knowledge-Based_Structural_Models_of_SARS-CoV-2_Proteins_and_Their_Complex_with_Potential_Drugs/12021330 Authors: Atsushi Hijikata, Clara Shionyu-Mitsuyama, Setsu Nakae, Masafumi Shionyu, Motonori Ota, Shigehiko Kanaya, Tsuyoshi Shirai |
Outline: The World Health Organization (WHO) has declared a pandemic of the 2019 novel coronavirus SARS-CoV-2 infection (COVID-19). There is, however, no confirmed anti-COVID-19 therapeutic currently. In order to assist structure-based discovery of repurposing drugs against this disease, knowledge-based models of SARS-CoV-2 proteins were constructed, and the ligand molecules in the template structures were compared with approved/experimental drugs and components of natural medicines. The models suggested several drugs, such as carfilzomib, sinefungin, tecadenoson, and trabodenoson, as potential drugs for COVID-19. (Last updated: 2020/06/05)
|
1. Report on key interactions between SARS-CoV-2 main protease and inhibitor drug candidates |
---|
Title: Identification of Key Interactions Between SARS-CoV-2 Main Protease and Inhibitor Drug Candidates Preprint server: ChemRxivPosted Date: 2020/03/23 URL: https://chemrxiv.org/articles/Identification_of_Key_Interactions_Between_SARS-CoV-2_Main_Protease_and_Inhibitor_Drug_Candidates/12009636 Authors: Ryunosuke Yoshino, Nobuaki Yasuo, Masakazu Sekijima |
Outline: We revealed key interactions between SARS-CoV-2 Mpro and three drug candidates by performing pharmacophore modeling and 1μs molecular dynamics (MD) simulations. 概要:
(Last updated: 2020/06/05)
|
最終更新日 令和2年6月24日